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Abstract
Background: C-Reactive Protein (CRP) has been shown to be an accurate biomarker for discriminating bacterial
from viral infections in febrile patients in Southeast Asia. Here we investigate the accuracy of existing rapid
qualitative and semi-quantitative tests as compared with a quantitative reference test to assess their potential for
use in remote tropical settings.
Methods: Blood samples were obtained from consecutive patients recruited to a prospective fever study at three
sites in rural Laos. At each site, one of three rapid qualitative or semi-quantitative tests was performed, as well as a
corresponding quantitative NycoCard Reader II as a reference test. We estimate the sensitivity and specificity of the
three tests against a threshold of 10 mg/L and kappa values for the agreement of the two semi-quantitative tests
with the results of the reference test.
Results: All three tests showed high sensitivity, specificity and kappa values as compared with the NycoCard Reader II.
With a threshold of 10 mg/L the sensitivity of the tests ranged from 87–98 % and the specificity from 91–98 %. The
weighted kappa values for the semi-quantitative tests were 0.7 and 0.8.
Conclusion: The use of CRP rapid tests could offer an inexpensive and effective approach to improve the targeting of
antibiotics in remote settings where health facilities are basic and laboratories are absent. This study demonstrates that
accurate CRP rapid tests are commercially available; evaluations of their clinical impact and cost-effectiveness at point
of care is warranted.
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Background
In most febrile patients presenting with non-specific
symptoms an accurate clinical diagnosis is not possible.
This is particularly challenging in the presence of diverse
aetiologies and inadequate diagnostic facilities, charac-
teristic of low income, malaria-endemic settings. While
malaria can be diagnosed with the aid of rapid diagnostic
tests (RDTs), the majority of fevers across much of the
malaria-endemic world have other causes [1–5]. These
patients commonly receive antibiotics when they are not
indicated, often for mild, self-limiting viral infections.
Conversely, antibiotics are often withheld from patients
they could benefit. This irrational and poorly targeted
use of antibiotics is a known contributor to the ever in-
creasing threat of antimicrobial resistance that plagues
global health [6].
Improving the management of non-malarial fevers is
also crucial for malaria elimination campaigns that neces-
sitate diagnosis and treatment of all remaining malaria
cases. In many areas in Asia community health worker
networks are being extended to support this aim. The
utilization of their services, however, is likely to suffer if
they are unable to influence the care of the majority of
patients with non-malarial causes of fever.
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C-reactive protein (CRP) is a non-specific marker of
inflammation. Use of CRP point-of-care tests to guide
the use of antibiotics in fevers and respiratory infections
in primary care is standard practice in a number of
high-income countries [7–10]. A recent analysis of over
1400 samples from fever studies in the Mekong region
confirmed the ability of CRP to distinguish between viral
and bacterial infections in these settings [11]. The quan-
titative readers used in high-income facilities, however,
might not be practical or affordable in rural tropical set-
tings. We evaluated three commercially available CRP
immunochromatographic rapid tests of a format that
could be used by community health workers in remote
settings to improve the management of non-malarial
fevers. This evaluation aims to provide a general
assessment of the reliability of the existing technology
underlying these tests to correctly classify patients as
having CRP values above or below the rapid test thresh-
old(s). Whether or not CRP is an effective guide for anti-
biotic treatment and the identification of appropriate
threshold(s) to inform patient management is the subject
of further clinical outcome studies.
Methods
Samples for this investigation were obtained from a fever
study in rural Laos aiming to provide a prospective
description of the clinical features and aetiology of fever
among consecutive outpatients attending three provin-
cial hospitals in the provinces of Salavan, Luang Namtha,
and Xieng Khouang over one year. Adults giving in-
formed consent or children (<18 years) whose parent or
guardian gave informed consent who presented with a
history of fever for ≤8 days and/or admission body
temperature ≥38°c were recruited. CRP readings were
not used to inform patient recruitment or management
as the role of CRP in guiding antibiotics in these settings
is still under investigation.
Two individuals carried out independent searches for
commercially available CRP rapid tests with analytical
ranges and thresholds relevant to the detection of bacter-
ial infections (>10 mg/L). Three of five available tests were
evaluated in this study, with two further tests under
current evaluation in another study. In each site one of
the three CRP RDTs and the reference test was performed
at point-of-care immediately after patient presentation.
Two of the sites used serum for both the RDT and the
reference test (DTS233, Creative Diagnostics, USA; WD-
23, Assure Tech, China). In a third site whole blood was
used for the RDT (bioNexia CRPplus, bioMérieux S.A.,
France) and EDTA plasma was used for the reference test
(see Table 1 for test characteristics). All tests were per-
formed and interpreted by a laboratory technician accord-
ing to the manufacturers’ instructions. In all sites a
NycoCard Reader II (Alere/Axis-Shield, Oslo, Norway)
for quantitative CRP readouts was used as a reference
test. The NycoCard Reader II has an analytical range of
5-120 mg/L using serum/plasma or 8-120 mg/L in
whole blood and its accuracy has previously been con-
firmed to be high [12], including in the context of
resource-poor settings [13]. Due to limited study
personnel at the sites, the RDTs and the reference tests
were carried out in an unblinded manner by the same
individual, with the RDT being interpreted prior to the
reference test to minimise the risk of bias.
Statistical analysis
The accuracy of the RDTs was calculated with respect to
the thresholds stated by each manufacturer. All three tests
shared a threshold of 10 mg/L to define positivity. The two
semi-quantitative tests had additional higher thresholds, of
either 30 or 40 mg/L, and of 80 mg/L. We calculated the
sensitivity and specificity of each of the three tests with a
binary interpretation of the result using the shared thresh-
old of 10 mg/L. Sensitivity was calculated as the number of
individuals with a positive RDT out of all patients with a
reference test result >10 mg/L and specificity as the num-
ber of individuals with negative RDT out of all those with a
reference test result of <10 mg/L. Confidence intervals for
sensitivity and specificity were calculated using the Wilson
score method. For the two semi-quantitative tests with
multiple thresholds we categorised patients according to
their reference test result using the RDT manufacturers’
specified thresholds, and used a weighted Kappa statistic
for the agreement in RDT classification as compared with
the NycoCard Reader II results [14]. The analysis was
carried out using Stata 14 (StataCorp. Texas, USA).
Ethical approval was obtained for the fever study from
the Lao National Ethics Committee for Health Research
and from the Oxford Tropical Ethics Committee
(OXTREC, reference 27–14). Both bodies also ap-
proved an amendment to the original protocol for this
sub-study. The Informed Consent form allowed for
samples to be used for microbiological and diagnostic
investigations.
Results
From the introduction of the RDTs in March 2015 up
until the end of July 2015, a total of 837 patients were
recruited into the fever study. Demographic and clinical
characteristics of these patients are described in Table 2.
In all sites fever was only present in one third of patients
at enrolment (35, 25.6, and 39.2 % in Salavan, Luang
Namtha and Xieng Khouang respectively). Respiratory
syndrome was the most frequent presentation, occurring
in 81.7 % of cases (82.1 % in Salavan, 85.2 % in Luang
Namtha, and 75.6 % in Xieng Khouang).
The overall prescription rate of antibiotics was 58.8 % in
all sites (44 % in Salavan, 72 % in Luang Namtha, and 51.5
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% in Xieng Khouang). Overall, penicillin A was the most
prescribed antimicrobial in 55.9 % of cases, followed by
cephalosporins (11.8 %). The Xieng Khouang site also had
the highest rate of pre-attendance antibiotics consumption
(31.1 %), compared with Salavan and Luang Namtha (15.3
and 23.8 % respectively).
Of these 837 patients, 82 % had fresh-blood samples
taken for CRP assays for immediate testing, at point-of-
care. The distributions of CRP levels in the three sites
according to the reference test are shown in Fig. 1. In
two of the sites (Salavan and Luang Namtha) the major-
ity of patients had CRP levels <10 mg/L, while in Xieng
Khouang 86 % of patients had CRP levels above this
threshold. A total of 167, 363 and 157 tests were carried
out for the DTS233, WD-23 and bioNexia CRPplus
tests, respectively. These data are plotted in Fig 2, along
with the manufacturer specified ranges with which each
test result is supposed to correspond.
Using the shared threshold of 10 mg/L and a binary in-
terpretation of the RDT results (either negative or positive
regardless of positivity category in the semi-quantitative
tests), all three RDTs had high sensitivity and specificity,
as shown in Table 3. The two semi-quantitative tests also
showed high agreement with the reference test result, with
weighted kappa values of 0.7 and 0.8 for the WD-23 and
the bioNexia CRPplus tests, respectively.
Discussion
Use of CRP rapid tests in remote settings could help en-
sure that patients in need of antibacterial treatment are
identified as such, while reducing unnecessary use of an-
timicrobials in viral infections. All three tests included in
this analysis exhibited high accuracy in line with their
manufacturers’ specified thresholds. Other tests are
available on the market; the selection of the three tests
was arbitrary, based on their accessibility to our research
units in Thailand and Laos.
All three tests had high accuracy when interpreted in a
binary manner. The semi-quantitative tests also per-
formed well in classifying patients into the specified
Table 1 Rapid test characteristics
Manufacturer Recommended
reading time
Format and thresholds Visual interpretation
DTS233 Creative
Diagnostics, USA
10 minutes, no more
than 15 minutes.
Qualitative, single
threshold of 10mg/L
WD-23 Assure Tech, China 5 minutes; no more
than 7 minutes.
Semi-quantitative;
<10mg/L; 10-30mg/L;
30-80mg/L; >80mg/L
A positive result and the classification determined
by the appearance and relative strength of the
test band as compared with the control and
reference bands.
bioNexia
CRPplus
bioMerieux,
France
Exactly 5 minutes Semi-quantitative;
<10mg/L; 10-40mg/L;
40-80mg/L; >80mg/L
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Fig. 1 Distribution of CRP levels in the three sites
Table 2 Demographic and clinical characteristics of patients at the baseline, according to study site
Patients at baseline
n=837
Sites in rural Laos
Salavan
(n=223)
Luang Namtha
(n=379)
Xieng Khouang
(n=S235)
Demographic characteristics
Male, n(%) 132 (59.2) 196 (51.7) 111 (47.2)
Age, median (IQR) 9 (1-27) 6 (1-23) 7 (1-25)
BMI (Kg/m2), mean (SD) 17.8 (3.88) 17.3 (4.23) 18.1 (4.16)
Pre-admission antibiotics consumption 34 (15.3) 118 (31.1) 56 (23.8)
Current antibiotics prescription, n (%) 98 (44.0) 273 (72.0) 121 (51.5)
-Penicillin M & V, n [%) 6 (6.1) 6 (2.2) 27 (22.3)
-Penicillin A, n (%) 31 (31.6) 225 (82.4) 19 (15.7)
-Cephalosporins, n (%) 20 (20.4) 13 (4.8) 25 (20.7)
-Quinolones, n (%) 24 (24.5) 14 (5.1) 8 (6.6)
-Macrolides, n (%) 7 (7.1) 11 (4.0) 10 (8.3)
-Others® [%) 10 (10.2) 4 (1.5) 32 (26.5)
Time (in days) between
Onset of symptoms & Admission
3 (2-4) 3 (2-5) 2 (1-4)
Clinical characteristics
Fever, n (%)* 78 (35.0) 97 (25.6) 92 (39.2)
Neurological presentation, n (%)** 105 (47.1) 220 (58.2) 180 (76.6)
Respiratory syndrome, n(%)*** 183 (82.1) 322 (85.2) 177 (75.6)
Enteric syndrom, n (%)**** 63 (28.3) 174 (46.0) 144 (61.3)
Undifferentiated fever, n (%)***** 6 (8.2) 4 (2.7) 4 (4.9)
* Fever defined by tympanic temperature >37.7°C
** Neurological syndrome includes the presence of at least one of these symptoms: stiffneck; cephalalgia; confusion
*** Respiratory syndrome includes the presence of at least one of these symptoms: lung crepitation; cough; dyspnoea
**** Enteric syndrom includes the presence of at least one of these symptoms: abdominal pain; vomiting; nausea; jaundice; diarrhoea
****** Undifferentiated fever includes the absence of any focal symptoms, coupled with the presence of at least one of these symptoms: fever; chills; rigors; myalgia
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range. In doing so they provide richer information that
could feed into more nuanced algorithms to guide the
use of antibiotics and decisions on referral. On the other
hand, the interpretation of semi-quantitative tests can be
more challenging and in the absence of a dedicated
reader a binary test might be preferred.
Whether a single threshold is sufficient and the opti-
mal value(s) to indicate the need for antibiotics and/or
referral is not well established. The threshold of 10 mg/L
is lower than most recommendations in high income
settings [7, 15], although for remote settings with limited
ability to follow patients up and obtain emergency care
it might be appropriate to accept a higher rate of false
positives. Further studies of CRP-guided treatment algo-
rithms are required to identify optimal threshold(s).
There are limitations to this study. First, the RDTs
used fresh serum and EDTA whole blood whereas if im-
plemented in routine care CRP RDTs are likely to be
performed on fresh whole blood. Second, in one site the
reference test used a different matrix than the RDT.
Third, due to restricted study personnel, the RDTs and
the reference test were performed by the same individ-
ual. Further work is being carried out on a broader range
of tests to address these limitations. Fourth, while pa-
tients were recruited prospectively into the study, in one
site many children did not have a blood sample taken.
This might partly explain the elevated CRP levels in this
site as compared with the other two sites; consultations
of children in primary settings often occur at an earlier
stage than adults because of parental behaviour [16].
The limited number of individuals with low levels of CRP
in this site resulted in a wide confidence interval of 71–99
% for the specificity of the RDT. Lastly, the NycoCard
Reader II was used as a reference test although ELISA
testing in reference laboratories might have provided more
accurate measurements. The NycoCard Reader has, how-
ever, been used in similar remote settings, with excellent
correlation with laboratory-based CRP [13].
Several questions are highlighted for further research.
The use of rapid CRP tests needs to be prospectively
evaluated in routine settings, including estimating their
accuracy using fresh whole blood; inter-observer agree-
ment; and the importance of timing. In a previous
evaluation of CRP tests it was shown that even small de-
lays in reading the test results can be detrimental to
their accuracy [17]. Most important, however, are inves-
tigations into the clinical implications of CRP-guided
treatment algorithms, to gauge whether they can safely
reduce antibiotic prescriptions without impacting ad-
versely on outcomes. The thresholds used in currently
available qualitative or semi-quantitative tests might not
be optimal for these purposes; further clinical and
Table 3 Accuracy of the three rapid tests as compared with the reference test
Sensitivity at a
threshold of 10mg/L
(CI)
Specificity at a
threshold of 10mg/L
(CI)
Unweighted
kappa
Weighted
kappa
DTS233 95% (87%-99%) 98% (92%-100%) 0.93 (51%) NA
CRP-W23 87% (79%-92%) 91% (87%-95%) 0.62 (80%) 0.7 (93%)
bioNexia CRPplus 98% (95%-100%) 91% (71%-99%) 0.68 (81%) 0.8 (93%)
Fig. 2 Results rapid tests in relation to the quantitative reference test
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economic evaluations are required to identify optimal
thresholds. Whether health workers and patients adhere
to CRP test results will also need to be determined. Not-
withstanding these questions, this analysis provides
further support to the possible implementation of CRP
rapid tests at point-of-care, in order to inform the man-
agement of febrile patients with a negative malaria test.
Conclusions
Over the last few years, widespread use of malaria rapid test
transformed the management of fevers in tropical settings.
Improved targeting of antimalarials, however, has been ac-
companied by increasing misuse of antibiotics, often pre-
scribed to patients they will not benefit, while treatable
infections go undetected. There is increasing evidence from
aetiological and clinical studies indicating that CRP testing
could contribute to better identification of patients that re-
quire treatment, while reducing overall drug pressure and
mitigate the spread of antimicrobial resistance.
This study evaluated simple lateral flow CRP tests that
could potentially be used in the most remote settings to
guide referral and treatment of non-malarial fevers. The
three tests performed well as compared with a quantitative
validated reader in detecting elevated levels of CRP. While
further research is required into the performance of such
tests in field conditions and to determine the optimal cut-
off threshold(s) for CRP guided treatment, the timeframe
to introduction of such tests could be relatively short.
New pathogen specific multiplex testing and/or other bio-
markers could again revolutionize the management of
fever in the long run, but until these become available
current practice can and should evolve using available
tests that are already routinely used in other settings.
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